For patients with obstructive sleep apnea (OSA), sleep surgery is associated with a significantly reduced risk for motor vehicle accidents (MVA) compared with continuous positive airway pressure (CPAP ...

ResMed Inc . (NYSE:RMD; ASX:RMD), a leading player in the sleep and respiratory care market, has demonstrated strong operational performance in recent quarters. However, the company faces potential ...

Sleep apnea affects over 29 million Americans, with Obstructive Sleep Apnea (characterized by pauses in breathing during ...

While Continuous Positive Airway Pressure (CPAP) machines have long been the standard treatment, many patients find them uncomfortable or difficult to use. Fortunately, Sleep Solution Centers, a ...

In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

Q2 2025 Earnings Call Transcript January 30, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Welcome to the Q2 Fiscal Year 2025 ResMed Earnings ...

Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...

ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.

Or could those jumping on the morning shed trend actually sabotage their beauty goals? We spoke to dermatologists and hair ...

The global sleep apnea devices market is set to expand at a steady CAGR of 9.5%, growing from USD 8.2 billion in 2023 to USD ...

My wife, who bore the brunt of my transformation into a grumpy badger, was the first to suggest I get a sleep study. She’d ...